Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: A long-term retrospective analysis

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 224-229

  Bonomi, M ^a   Nortilli, R ^a   Molino, A ^b   Sava, T ^b   Santo, A ^b   Caldara, A ^a   Cetto, G L ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Bisphosphonate; Nephrotoxicity; Osteonecrosis of the jaw; Pamidronate; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CREATININE; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHRONIC DRUG ADMINISTRATION; CREATININE BLOOD LEVEL; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; JAW OSTEONECROSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 77956929667     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9195-y     Document Type: Article

References (31)

1. Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004;9((suppl 4)):14-27. doi:10.1634/theoncologist.9-90004-14. (Pubitemid 39363165)
2. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol. 1996;14:2552-9.
3. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Sinoff C, Wheeler H, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Eng J Med. 1996;335:1785-91. doi:10.1056/NEJM199612123352401. (Pubitemid 26412396)
4. Hortobagyi GN, Theriault RL, Lipton A, Porter R, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol. 1998; 16:2038-44.
5. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Eng J Med. 1996;334:488-93. doi:10.1056/ NEJM199602223340802. (Pubitemid 26067736)
6. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol. 1998;16:593-602.
7. Rosen LS, Gordon D, Kaminsky M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double blind, comparative trial. Cancer J. 2001;7(5):377-87.
8. Rosen LS, Gordon D, Kaminsky M, Howell A, Belch A, Mackey J, et al. Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer. 2003;98(8):1735-44. doi:10.1002/cncr.11701. (Pubitemid 37238631)
9. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-68.
10. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long term efficacy and safety of zoledronic acid in the treatment of skeletal metastasis in patients with nonsmall cell lung carcinoma and other solid tumors. A randomized, phase III, double blind, placebo controlled trial. Cancer. 2004; 100:2613-21. doi:10.1002/cncr.20308. (Pubitemid 38715767)
11. Tanvetyanon T, Stiff PJ. Managment of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006; 17:897-907. doi:10.1093/annonc/ mdj105. (Pubitemid 43785797)
12. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic (letterto the editor). J Oral Maxillofac Surg. 2003;61:1115-7. doi: 10.1016/S0278-2391(03)00720-1. (Pubitemid 37064711)
13. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaw associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34. doi: 10.1016/j.joms.2004.02.004. (Pubitemid 38542516)
14. Migliorati CA, Siegel MA, Elting LS. Bisphosphonates-associated osteonecrosis: a long term complication of bisphosphonate treatment. Lancet. 2006;7:508-14.doi:10.1016/S1470-2045(06)70726-4. (Pubitemid 43779167)
15. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg. 2005;63:682-9. doi:10.1016/j.joms.2005.01.010. (Pubitemid 40602707)
16. Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2006;2:7-14. doi:10.1200/JOP.2.1.7.
17. American Association of Oral, Maxillofacial Surgeons'. Position paper on bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg. 2007;65:369-76.
18. Bagan J, Blade J, Cozar JM, Constela M, García Sanz R, Gómez Veiga F, et al. Recommendations for the prevention diagnosis and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007;12:E336-40.
19. Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos I, Antoniadis K, et al. Osteonecrosis of the jaws due to bisphosphonate use: a review of 60 cases and treatment proposals. Am J Otolaryngol Head Neck Med Surg. 2007;28: 158-63.
20. Agrillo A, Petrucci MT, Tedaldi M, Mustazza MC, Marino SMF, Gallucci C, et al. New therapeutic protocol in the treatment of avascular necrosis of the jaws. J Craniofac Surg. 2007;17(6): 1080-3. doi:10.1097/01.scs.0000249350.59096. d0.
21. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042-57. doi:10.1200/JCO.2003.08.017.
22. Guarneri V, Donati S, Nicolini M, Giovannelli S, D'Amico R, Conte PF. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated up to 10 years. Oncologist. 2005;10:842-8. doi:10.1634/theoncologist.10-10-842. (Pubitemid 43152702)
23. Ali SM, Esteva FJ, Hortobagiy G, Harvey H, Seaman J, Knight R, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol. 2001;19(14):3434-7.
24. Bujanda DA, Sarmiento UB, Cabrera Suarez MA, Aguiar Morales J. Assesment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastases. Ann Oncol. 2006;18:556-60. doi:10.1093/annonc/mdl408.
25. Khono N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:1-8.
26. Van den Wyngaert T, Huizing MT, Vermoken JB. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol. 2006;17:1197-204. doi:10.1093/annonc/mdl294. (Pubitemid 44288209)
27. Sanna G, Preda L, Bruschini R, Cossu Rocca M, Ferretti S, Adamoli L, et al. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol. 2006;17:1512-6. doi:10.1093/annonc/mdl163. (Pubitemid 44542036)
28. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580-7. doi:10.1200/JCO.2005. 02.8670. (Pubitemid 46211499)
29. Durie GM, Katz M, Crowley J. Osteonecrosis of the jaws and bisphosphonates (letter to the editor). N Eng J Med. 2005;335: 99-100. doi:10.1056/NEJM200507073530120. (Pubitemid 41007817)
30. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population based analysis. J Natl Cancer Inst. 2007; 99:1016-24. doi:10.1093/jnci/djm025. (Pubitemid 47240676)
31. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg. 2005;63:1567-75. doi:10.1016/j.joms.2005.07.010. (Pubitemid 41525412)